Bristol-Myers Squibb Company


Want a discount? Become a member by purchasing Annual Subscription!
SKU: BMY Category:


Bristol-Myers Squibb has had a particularly rough 2020. The company’s drug sales were hit badly by the COVID-19 pandemic as the lockdowns prevented consumers from having access to doctor’s offices, hospitals, and infusion centres. The company’s revenues are currently being driven by 3 of its blockbuster drugs – Revlimid (blood cancer drug), Opdivo (immuno-oncology drug), and Eliquis (blood thinning drug). However, with the company losing the exclusivity of each of these in the coming years, the management is working hard on new launches in order to ensure that the top-line growth remains strong.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $496 annual subscription!